Cancer Antigen 27.29
Also known as: CA27.29
Use
The CA 27.29 assay is intended for use in monitoring disease progression and/or response to therapy in patients with metastatic breast cancer, and disease recurrence in patients previously treated for stages II or III breast carcinoma who are clinically free of the disease. It should be used in conjunction with other clinical methods for early detection of cancer recurrence, rather than diagnosis or screening.
Special Instructions
Serial testing in patients clinically free of disease is recommended to be used alongside other clinical methods for detecting cancer recurrence. Results obtained with different assay methods or kits are not interchangeable.
Limitations
Patients with confirmed breast carcinoma may have CA 27.29 assay values that overlap with those of healthy individuals. Elevated levels might also be observed in patients with non-malignant diseases. It is critical that test results are interpreted within the context of morphologic and other relevant clinical data, and not used in isolation to diagnose malignancy.
FDA ApprovedNew York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 17842-6
Result Turnaround Time
1 day
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Allow specimen to clot completely at room temperature. Separate serum from cells as soon as possible, within 2 hours of collection.
Storage Instructions
Frozen.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 7 days |
| Frozen | 3 months |
Other tests from different labs that may be relevant